CD19-directed CAR T-cell-based therapy has been successful in treating several B-cell lineage malignancies, including systemic diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (ML), and follicular lymphoma (FL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.